7 completed, 4 terminated, 1 active not recruiting. 8 Phase 3, 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Terminated 3, Active not recruiting 1 |
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
| Phase 1 | 1 | Terminated 1 |
Follow solanezumab: new trials by email Literature Review of solanezumab trials Research Report on solanezumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease Solanezumab, Placebo - Alzheimer's Disease | Phase 3 | Terminated | Eli Lilly and Company | 26 | 2016-06-01 | 2019-10-10 |
| A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) LY2599666, Solanezumab, Placebo SC - Healthy, Alzheimer's Disease | Phase 1 | Terminated | Eli Lilly and Company | 50 | 2015-12-01 | 2020-06-17 |
| Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Placebo, Solanezumab - Cognition Disorders | Phase 3 | Completed | Eli Lilly and Company | 1169 | 2014-02-28 | 2026-08-21 |
| Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Solanezumab, Placebo - Alzheimer's Disease | Phase 3 | Terminated | Eli Lilly and Company | 2129 | 2013-07-01 | 2019-10-09 |
| Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab) - Alzheimers Disease, Dementia | Phase 2 / Phase 3 | Active not recruiting | Washington University School of Medicine | 490 | 2012-12-01 | 2026-07-27 |
| Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab) - Alzheimers Disease, Dementia | Phase 2 / Phase 3 | Completed | Washington University School of Medicine | 194 | 2012-12-01 | 2022-09-22 |
| Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease Solanezumab, Placebo - Alzheimer's Disease | Phase 3 | Terminated | Eli Lilly and Company | 1457 | 2010-12-01 | 2019-10-08 |
| A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's solanezumab - Alzheimer's Disease | Phase 2 | Completed | Eli Lilly and Company | 55 | 2010-08-01 | 2012-09-25 |
| Effect of LY2062430 on the Progression of Alzheimer's Disease LY2062430, Placebo - Alzheimer's Disease | Phase 3 | Completed | Eli Lilly and Company | 1000 | 2009-05-01 | 2012-09-25 |
| Effect of LY2062430 on the Progression of Alzheimer's Disease LY2062430, Placebo - Alzheimer's Disease | Phase 3 | Completed | Eli Lilly and Company | 1040 | 2009-05-01 | 2012-12-13 |
| Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease Solanezumab - Alzheimer's Disease | Phase 2 | Completed | Eli Lilly and Company | 33 | 2008-09-01 | 2010-06-02 |
| Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers LY2062430, Placebo - Alzheimer's Disease | Phase 2 | Completed | Eli Lilly and Company | 25 | 2006-05-01 | 2009-10-07 |
Alzheimer Disease (11) · Dementia (2) · Cognition Disorders (1) · Cognitive Dysfunction (1)
Eli Lilly and Company (10) · Washington University School of Medicine (2)
United States (11) · Japan (9) · Canada (7) · Australia (6) · France (6) · Spain (6) · United Kingdom (6) · Germany (5) · Italy (5) · Poland (4) · Sweden (4) · Argentina (3) · Brazil (3) · Puerto Rico (3) · Taiwan (3)
PMID 36946603, PMID 40603145, PMID 24450890, PMID 25125457, PMID 26120369, PMID 26402769, PMID 29615123, PMID 29365294, PMID 35197359, PMID 35543002, PMID 36110925, PMID 37017737, PMID 37458272, PMID 38230716, PMID 38683602, PMID 39044494, PMID 39044495, PMID 39044496, PMID 39044497, PMID 39974075, PMID 40120616, PMID 40440591, PMID 40476544, PMID 40985290, PMID 40990131, PMID 41001450, PMID 41085172, PMID 41537338, PMID 41926844, PMID 41963989, PMID 42295275, PMID 42657501
R01AG046179 (2), U01AG042791 (2), 2016 (1), R01AG053267 (1), R56AG053267 (1), U01AG059798 (1)